Melita Salkovic-Petrisic1, Ana Knezovic2, Jelena Osmanovic-Barilar2, Una Smailovic2, Vladimir Trkulja2, Peter Riederer3, Tamar Amit4, Silvia Mandel5, Moussa B H Youdim4. 1. Department of Pharmacology and Croatian Institute for Brain Research, University of Zagreb School of Medicine, Salata 11, HR 10 000 Zagreb, Croatia. Electronic address: melitas@mef.hr. 2. Department of Pharmacology and Croatian Institute for Brain Research, University of Zagreb School of Medicine, Salata 11, HR 10 000 Zagreb, Croatia. 3. University Hospital Wuerzburg, Center of Mental Health, Department of Clinical Neurochemistry, Clinic and Policlinic of Psychiatry, Psychosomatic and Psychotherapy, University of Wuerzburg, Fuechsleinstr. 15, 97080 Wuerzburg, Germany. 4. Eve Topf Center for Neurodegenerative Diseases Research and Department of Molecular Pharmacology, Faculty of Medicine, Technion, Haifa, Israel. 5. Bruce Ruth Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel.
Abstract
AIM: Novel effective treatment is urgently needed for sporadic Alzheimer's disease (sAD). M30 ([5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline]) and HLA-20 (5-{4-propargylpiperazin-1-ylmethyl}-8-hydroxyquinoline) are brain permeable, iron chelating compounds with antioxidant activity, showing also neuroprotective activity in animal models of neurodegeneration.Weaimed to explore their therapeutic potential in non-transgenic (non-Tg) rat model of sAD developed by intracerebroventricular administration of streptozotocin (STZ-icv). MAIN METHODS: Therapeutic effects of chronic oral M30 (2 and 10 mg/kg) and HLA20 (5 and 10 mg/kg) treatment on cognitive impairment in STZ-icv rat model were explored by Morris Water Maze (MWM) and Passive Avoidance (PA) tests in neuropreventive and neurorescue paradigms. Data were analysed by Kruskal–Wallis and Mann–Whitney U test (p b 0.05). KEY FINDINGS: Five-day oral pre-treatment with M30 and HLA20 dose-dependently prevented development of spatial memory impairment (MWM probe trial-time +116%/M30; +60%/HLA20) in STZ-icv rat model (p b 0.05). Eleven-week oral treatment with M30 (3×/week), initiated 8 days after STZ-icv administration dosedependently ameliorated already developed cognitive deficits in MWM test (reduced number of mistakes 3 months after the STZ-icv treatment — 59%; p b 0.05) and fully restored them in PA test (+314%; p b 0.05). Chronic M30 treatment fully restored (−47%/PHF1;−65%/AT8; p b 0.05) STZ-induced hyperphosphorylation of tau protein and normalized decreased expression of insulin degrading enzyme (+37%; p b 0.05) in hippocampus. SIGNIFICANCE: The results provide first evidence of therapeutic potential of M30 and HLA20 in STZ-icv rat model of sAD with underlying molecular mechanism, further supporting the important role of multi-target ironchelators in sAD treatment.
AIM: Novel effective treatment is urgently needed for sporadic Alzheimer's disease (sAD). M30 ([5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline]) and HLA-20 (5-{4-propargylpiperazin-1-ylmethyl}-8-hydroxyquinoline) are brain permeable, iron chelating compounds with antioxidant activity, showing also neuroprotective activity in animal models of neurodegeneration.Weaimed to explore their therapeutic potential in non-transgenic (non-Tg) rat model of sAD developed by intracerebroventricular administration of streptozotocin (STZ-icv). MAIN METHODS: Therapeutic effects of chronic oral M30 (2 and 10 mg/kg) and HLA20 (5 and 10 mg/kg) treatment on cognitive impairment in STZ-icvrat model were explored by Morris Water Maze (MWM) and Passive Avoidance (PA) tests in neuropreventive and neurorescue paradigms. Data were analysed by Kruskal–Wallis and Mann–Whitney U test (p b 0.05). KEY FINDINGS: Five-day oral pre-treatment with M30 and HLA20 dose-dependently prevented development of spatial memory impairment (MWM probe trial-time +116%/M30; +60%/HLA20) in STZ-icvrat model (p b 0.05). Eleven-week oral treatment with M30 (3×/week), initiated 8 days after STZ-icv administration dosedependently ameliorated already developed cognitive deficits in MWM test (reduced number of mistakes 3 months after the STZ-icv treatment — 59%; p b 0.05) and fully restored them in PA test (+314%; p b 0.05). Chronic M30 treatment fully restored (−47%/PHF1;−65%/AT8; p b 0.05) STZ-induced hyperphosphorylation of tau protein and normalized decreased expression of insulin degrading enzyme (+37%; p b 0.05) in hippocampus. SIGNIFICANCE: The results provide first evidence of therapeutic potential of M30 and HLA20 in STZ-icvrat model of sAD with underlying molecular mechanism, further supporting the important role of multi-target ironchelators in sAD treatment.
Entities:
Keywords:
Alzheimer's disease; HLA20 compound; Insulin degrading enzyme; M30 compound; Memory; Streptozotocin; Tau protein
Authors: Lisa Baldauf; Thomas Endres; Johannes Scholz; Elmar Kirches; Diane M Ward; Volkmar Lessmann; Katrin Borucki; Christian Mawrin Journal: Neurosci Lett Date: 2019-09-26 Impact factor: 3.046
Authors: María F Zappa Villar; Juliette López Hanotte; Joaquín Pardo; Gustavo R Morel; Guillermo Mazzolini; Mariana G García; Paula C Reggiani Journal: Mol Neurobiol Date: 2019-08-10 Impact factor: 5.590
Authors: María F Zappa Villar; Juliette López Hanotte; Eugenia Falomir Lockhart; Lucía S Trípodi; Gustavo R Morel; Paula C Reggiani Journal: J Neural Transm (Vienna) Date: 2018-09-22 Impact factor: 3.575
Authors: Mercedes Unzeta; Gerard Esteban; Irene Bolea; Wieslawa A Fogel; Rona R Ramsay; Moussa B H Youdim; Keith F Tipton; José Marco-Contelles Journal: Front Neurosci Date: 2016-05-25 Impact factor: 4.677